Longevity Market Expansion Elysium Health is actively expanding with new locations, including the opening of The Elysium Longevity Institute in New York in 2026, signaling a broader footprint and potential collaboration opportunities with clinics, physicians, and wellness programs in major markets.

Product Pipeline Growth A steady stream of product launches across 2024–2026 such as COFACTOR, CREATINE+, and Vision indicates a diverse product portfolio targeting NAD+ biology, collagen support, eye health, and longevity, offering multiple touchpoints for B2B partnerships, white-label opportunities, or clinical study collaborations.

Clinical Evidence Focus Elysium emphasizes research and human clinical trials to demonstrate safety and efficacy, which can be leveraged in partnerships with healthcare providers, payers, and research institutions seeking evidence-based nutraceuticals and longevity interventions.

Strategic Advisory A Scientific Advisory Board with Nobel laureates and experts across chemistry, physiology, neuroscience, and biochemistry provides credibility for co-development, sponsored studies, and advisory roles with potential customers seeking trusted science-backed products.

Financially Viable Partners With revenue in the 10–25 million range and substantial funding of 71 million, Elysium presents a financially viable partner for joint ventures, licensing deals, or distribution partnerships, especially in the growing longevity and wellness market.